Journal
Nonresident Licences: The Board You Did Not Expect
Two boards are involved in most mail-order prescriptions and they hold different records.
Two boards are involved in most mail-order prescriptions and they hold different records. This piece sets out what is established on nonresident pharmacy licence, which record holds it, and what remains unverified — with the underlying figures published as tables and charts so the reasoning is checkable rather than asserted.
Key findings
- Two boards are involved in most mail-order prescriptions and they hold different records.
- Every figure here is drawn from a dated capture or an FDA primary source.
- Regulatory framework and entity-specific claims are held to different evidence standards.
- Open fields render as explicit statuses, never as estimates.
- No provider pays for coverage or placement on this platform.
| Topic | nonresident pharmacy licence |
|---|---|
| Category | Regulation |
| Pricing captured | 2026-07-06 |
| Framework sources | FDA, verified 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
Two boards, two records
A pharmacy shipping into a state generally needs a nonresident licence from that state as well as its home-state licence. Almost every state operates such a scheme.
Nonresident licences expire and are disciplined independently. Verifying one does not verify the other, and the board holding the relevant record may not be the one you would expect.
What the rule actually says?
Compounding a drug that is essentially a copy of a commercially available approved product is restricted under both section 503A and section 503B. The restriction exists to protect the approval system: if a compounder could freely reproduce an approved drug, the incentive to run trials and seek approval would collapse.
The operative phrase is 'commercially available'. While a drug sits on the FDA shortage list it is, by definition, not adequately available — and the restriction lifts. That single mechanism created the entire compounded GLP-1 market and then closed it.
Section 503B restricts producing a drug product that is essentially a copy of an approved drug product. FDA
Timeline data as a table
| March 2022 | Semaglutide (Wegovy) added to the FDA drug shortage list. |
|---|---|
| August 2022 | Ozempic (semaglutide) added to the shortage list. |
| December 2022 | Tirzepatide (Mounjaro, Zepbound) added to the shortage list. |
| 2 October 2024 | FDA declares the tirzepatide shortage resolved. |
| 19 December 2024 | FDA reaffirms resolution by declaratory order. |
| 18 February 2025 | 503A enforcement discretion for tirzepatide ends. |
| 21 February 2025 | FDA removes semaglutide injection from the shortage list. |
| 5 March 2025 | Court denies preliminary injunction, Outsourcing Facilities Association v. FDA. |
| 19 March 2025 | 503B enforcement discretion for tirzepatide ends. |
| 24 April 2025 | Court denies a further preliminary injunction. |
| 30 April 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. |
| 29 June 2026 | Comment docket on the bulks-list proposal closes. |
Why the dates matter more than the rule?
Regulatory change in this sector is dated, not gradual. Each step below changed what could lawfully be produced on a specific day, and the 503A and 503B deadlines were a month apart — so a pharmacy and an outsourcing facility operated under different rules through February and March 2025.
The April 2026 bulks-list proposal is different in kind. It would foreclose the route permanently rather than until the next shortage, which is why it matters more than its coverage suggested.
Chart data as a table
| FL | 16 |
|---|---|
| TX | 16 |
| NJ | 10 |
| CA | 7 |
| PA | 5 |
| CO | 4 |
| MO | 3 |
| AZ | 3 |
| AR | 3 |
| OH | 3 |
What this means for a buyer?
A seller still offering these preparations is operating on one of three bases: a narrow patient-specific 503A argument, a claim that the preparation is not a copy, or nothing defensible at all. The first two are answerable questions and the third is visible from the refusal to answer.
Ask which pharmacy dispenses, by legal name and state licence number. That single question resolves more than any amount of reading about the regulations.
What would change this analysis?
Three things would. A final determination on the 503B bulks list proposal, which the closed docket now makes likely within months. A change in the approved-product pricing that has repriced the category — the $149 oral tier is recent and competitive pressure has been moving it. And any published pharmacokinetic work on compounded preparations, which would move several questions here from unmeasured to measured.
None of those is speculative. Each has a named decision-maker and, in two cases, a live process. This page carries its own date so the gap between what was checked and what is current stays visible.
How to check any of this yourself
Regulatory framework: FDA's compounding pages carry the statutory position and the declaratory orders that ended the shortage exception. Every framework claim on this platform links to one of them.
Facility status: FDA's registered outsourcing facility list is updated weekly and now publishes inspection dates, whether a Form 483 was issued, and the action status. State licensure sits with the relevant board of pharmacy — a different register, and the only one covering 503A pharmacies.
Pricing: every figure here is a dated capture against the provider's own published page, computed as a total. The full dataset is published as JSON and CSV so the arithmetic can be rerun.
Applying this to nonresident pharmacy licence
Two boards are involved in most mail-order prescriptions and they hold different records.
Everything above is checkable against a named public record. Where this platform has not performed that check, the field renders as an explicit status rather than an inferred value — which tells you precisely what to go and confirm.
What this means
- Regulatory framework and dates are cited to FDA primary sources.
- Pricing figures are dated captures against provider pages, computed as totals.
- Every open field carries an explicit status rather than an estimate.
What this does not mean
- That any named entity is compliant, safe, or non-compliant.
- That a lower price indicates better evidence or quality.
- That this platform certifies or endorses any facility or preparation.
- Pricing captured 2026-07-06; confirm at checkout before relying on it.
- Regulatory positions change through rulemaking, guidance and enforcement action.
- Entity-specific licence and enforcement records are covered on the monitoring pages, not here.
- Nothing here is legal or medical advice.
Frequently asked questions
What is the short answer on nonresident pharmacy licence?
Two boards are involved in most mail-order prescriptions and they hold different records.
Where do these figures come from?
Pricing from dated captures against provider pages (2026-07-06); regulatory facts from FDA primary sources.
Does any provider pay to appear here?
No. This platform has no affiliate, referral, sponsorship, or financial relationship with any provider.
How often is this updated?
When the underlying capture or regulatory position changes. Every page carries its own date.
Is this legal or medical advice?
No. It reports what named public records say on the dates they were checked. Clinical decisions belong with a prescriber and legal questions with a qualified adviser.
How can I check the figures myself?
The pricing dataset is published as JSON and CSV, the FDA register and inspection records are linked on every page that uses them, and each figure carries its capture date.
What if a record here is wrong?
Report it through the corrections process. Named entities can also respond through the right-to-respond route, and accepted corrections are logged with their date.
Sources
- GLP-1 pricing database
- FDA — Registered Outsourcing Facilities
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.